Full-Time

Software Engineer

Endoscopic Imaging Application Software

Confirmed live in the last 24 hours

Calyxo

Calyxo

201-500 employees

Develops medical devices for kidney stone treatment

Compensation Overview

$143k - $160k/yr

+ Variable Incentive Plan

Mid, Senior

Pleasanton, CA, USA

In Person

Category
Embedded Engineering
Full-Stack Engineering
Software Engineering
Required Skills
Python
CUDA
Data Structures & Algorithms
C/C++
Computer Vision
Linux/Unix
Requirements
  • Direct experience with CUDA and GPU programming
  • Strong understanding of computer vision fundamentals and image processing techniques
  • Familiarity with NVIDIA platforms (e.g., Jetson, DRIVE, or related SDKs)
  • Advanced experience with C++ Software Development (3-5 years)
  • Strong experience with Python
  • Experience working in a Linux based environment, specifically in a command line environment
  • Bachelor’s degree in Computer Science, Engineering, Math or a STEM discipline and a minimum 3-5 years' experience. Alternatively, minimum of 6 years professional experience developing software for products released to and used by customers
  • Deep understanding of Software Engineering principles such as object-oriented analysis and design, data structures, algorithms and software architecture
  • Proven track record with unit testing, module and integration testing
  • Excellent documentation skills paired with willingness to actively employ these skills
  • Excellent communication skills and ability to work independently and effectively within a team environment
  • Compliance with relevant county, state, and Federal rules regarding vaccinations.
Responsibilities
  • Design, architect and implement real time endoscopic imaging applications including user interface elements on embedded microprocessors
  • Actively implement and support optimization of high-performance computer vision algorithms for real time endoscopic imaging on medical devices using C++ and CUDA
  • Support the implementation of camera image signal and calibration pipelines for image quality enhancement
  • Collaborate with a cross-functional team of computer vision and electrical engineering specialists
  • Translate high level software requirements into detailed and thoroughly documented software implementations
  • Participate in design and code reviews. Contribute to design verification activities to prove that the software correctly implements requirements
  • Collaborate with program management to create accurate software project schedules and mentor other engineers
  • Define and lead implementation of best practices
  • Provide architectural guidance
  • Evaluate new technologies and provide architectural guidance

Calyxo develops medical devices specifically designed to treat kidney stones. Their products focus on improving the effectiveness and safety of treatment options available to urologists. By collaborating with leading urologists, Calyxo ensures that their devices meet the real clinical needs of healthcare providers. Unlike many competitors, Calyxo emphasizes a strong partnership with medical professionals to enhance patient care and clinical outcomes. The company's goal is to provide advanced solutions that make kidney stone treatment more efficient and effective, ultimately improving the overall experience for both patients and healthcare providers.

Company Size

201-500

Company Stage

Series D

Total Funding

$97.2M

Headquarters

Pleasanton, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA clearance for the redesigned CVAC System boosts market credibility and adoption.
  • Rising prevalence of kidney stones expands Calyxo's potential customer base.
  • Series D funding of $50M supports further innovation and market expansion.

What critics are saying

  • Emerging competition may impact Calyxo's market share in kidney stone treatments.
  • Economic downturns could reduce healthcare spending on new medical devices.
  • Rapid technological advancements require Calyxo to continuously innovate to stay competitive.

What makes Calyxo unique

  • Calyxo's CVAC System offers superior stone clearance compared to standard URS.
  • The company focuses on minimally invasive kidney stone treatments with high patient satisfaction.
  • Calyxo collaborates with leading urologists to enhance R&D and device innovation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

3%

2 year growth

1%
Business Wire
May 14th, 2024
Study Presented At Aua Shows Superior Kidney Stone Clearance Rates For Sure Procedure Using Calyxo’S Cvac System Vs Standard Urs

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, has announced that positive study results for its CVAC System were presented last week at the American Urological Association (AUA) Annual Meeting in San Antonio. The CVAC System, a revolutionary technology that is designed for complete kidney stone removal, was the focus of the prospective, randomized, multi-center ASPIRE study, which compared the safety and efficacy of steerable ureteroscopic renal evacuation (SURE) vs ureteroscopy (URS) with basketing. The 30-day results of the ASPIRE study were presented at the AUA Meeting by urologist Thomas Chi, MD of the University of California, San Francisco. In 101 patients, SURE demonstrated statistically superior stone clearance and significantly lower residual stone volume compared to standard URS. Unlike standard URS, the CVAC System achieved these results independent of baseline stone burden. Safety was comparable between groups

Business Wire
Mar 26th, 2024
Calyxo Announces Fda Clearance For New, Redesigned Cvac System

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, announced that it has received FDA clearance for its new, redesigned CVAC System, which enables a minimally invasive approach to kidney stone treatment. More than 50 procedures have already been completed by 12 urologists with the new CVAC System, yielding strong patient outcomes and consistently positive physician feedback. Clinical studies have shown that residual stone fragments are associated with a 20%-44% incidence of post-procedure problems, including pain, infection, emergency department visits, hospitalization and need for retreatment. Steerable ureteroscopic renal evacuation (SURE) using the original CVAC Aspiration System has been used to successfully treat more than 1,500 patients in the U.S., demonstrating that vacuum aspiration of stone fragments improves clinical outcomes, with 97% volumetric stone clearance and a high likelihood of avoiding the need for a secondary or more invasive procedure (according to clinical study data collected in patients treated with the device)

Finsmes
Dec 12th, 2023
Calyxo Raises $50M in Series D Funding

Calyxo, a Pleasanton, CA-based medical device company developing next-generation treatment solutions for patients with kidney stones, raised $50M in Series D funding.

Questa Capital
Jul 6th, 2022
Questa Capital invests into Calyxoinc in $32.7M

Calyxo, Inc., a medical device company focused on improving care for patients with kidney stones by delivering next generation treatment solutions, has announced the closing of a $32.7 million Series C financing round led by Questa Capital and CRG.

Business Wire
Jul 6th, 2022
Calyxo Raises $32.7 Million In Series C Financing To Support Novel Approach To Treating Kidney Stones

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company focused on improving care for patients with kidney stones by delivering next generation treatment solutions, has announced the closing of a $32.7 million Series C financing round led by Questa Capital and CRG. Calyxo has developed the innovative CVAC Aspiration System that utilizes irrigation and aspiration to remove kidney stones with the goal of a surgically stone-free outcome, a challenge that has always been difficult to achieve consistently